In one paragraphArticle in Clinical transplantation, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
11 authors.
Lee Ann Baxter-LoweUniversity of Southern California and Children's Hospital Los Angeles, Los Angeles, California, USA.ORCID 0000-0002-6706-0273 Tao WangDivision of Biostatistics, Data Science Institute, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.ORCID 0000-0002-2596-6843 Michelle KuxhausenCIBMTR® (Center for International Blood and Marrow Transplant Research), NMDP, Minneapolis, Minnesota, USA.
Stephen R SpellmanCIBMTR® (Center for International Blood and Marrow Transplant Research), NMDP, Minneapolis, Minnesota, USA.ORCID 0000-0002-7271-8252 Martin MaiersCIBMTR® (Center for International Blood and Marrow Transplant Research), NMDP, Minneapolis, Minnesota, USA.ORCID 0000-0002-0198-2064 Stephanie LeeCIBMTR® (Center for International Blood and Marrow Transplant Research), Medical College of Wisconsin, Milwaukee, Wisconsin, USA.ORCID 0000-0003-2600-6390 Jennifer SaultzDivision of Hematology/Oncology, Oregon Health and Science University, Portland, Oregon, USA.ORCID 0000-0003-0024-9466 Esteban Arrieta-BolañosInstitute for Experimental Cellular Therapy, University Hospital Essen, Essen, Germany.ORCID 0000-0002-3696-5803 Shahinaz M GadallaDivision of Cancer Epidemiology & Genetics, NIH-NCI Clinical Genetics Branch, Rockville, Maryland, USA.ORCID 0000-0002-3255-8143 Yung-Tsi BolonCIBMTR® (Center for International Blood and Marrow Transplant Research), NMDP, Minneapolis, Minnesota, USA.ORCID 0000-0001-9414-6120 Funding
Data Resource for Analyzing Blood &Marrow TransplantsU24CA076518 · NCI · MEDICAL COLLEGE OF WISCONSIN · PI Amy M Moskop, Bronwen Shaw · 1998 to 2026
$105.2MNTP INFORMATION SYSTEMS SUPPORT27305C0011 · NIEHS · Z-TECH CORPORATION · 2007 to 2009
$4.3MPROVIDE RABBITS, RATS, MICE, HAMSTERS, GERBILS, GUINEA PIGS27307C0011 · NIEHS · PI BOLEN, WAYNE · 2007 to 2007
$500kAbbVieActinium Pharmaceuticals, Inc.Adaptive Biotechnologies CorporationADC TherapeuticsAdienne SAAlexionAlloVir, Inc.Amgen, Inc.Astellas Pharma USAstraZenecaAtara BiotherapeuticsBeiGeneBioLineRXbluebird bio, inc.Blueprint MedicinesBlue Spark TechnologiesBristol Myers Squibb Co.CareDx Inc.CSL BehringCytoSen Therapeutics, Inc.DKMSEditas MedicineElevance HealthEurofins Viracor, DBA Eurofins Transplant DiagnosticsGamida-Cell, Ltd.Gateway for Cancer ResearchGift of Life BiologicsGift of Life Marrow RegistryGlaxoSmithKlineHistoGeneticsHRSA HHS 75R60222C00011Incyte CorporationIovanceJanssen/Johnson & JohnsonJanssen Research & Development, LLCJasper TherapeuticsJazz Pharmaceuticals, Inc.KariusKashi Clinical LaboratoriesKiadis PharmaKite, a Gilead CompanyKyowa KirinLabcorpLegend BiotechMallinckrodt PharmaceuticalsMedac GmbHMedical College of WisconsinMed Learning GroupMerck & Co.MesoblastMillennium, the Takeda Oncology Co.Miller Pharmacal Group, Inc.Miltenyi BiomedicineMiltenyi Biotec, Inc.MorphoSysMSA-EDITLifeNational Institute of Allergy and Infectious DiseasesNCI NIH HHS U24 CA076518Neovii Pharmaceuticals AGNHLBI NIH HHSNIEHS NIH HHS 27305C0011NIEHS NIH HHS 27307C0011NIEHS NIH HHS 27398C0011NMDPNovartis Pharmaceuticals CorporationOffice of Naval Research N00014-23-1-2057Office of Naval Research N00014-24-1-2057Omeros CorporationOptumHealthOrca Biosystems, Inc.OriGen BioMedicalOssium Health, Inc.Pediatric Transplantation and Cellular Therapy ConsortiumPfizer, Inc.Pharmacyclics, LLC, An AbbVie CompanyPPD Development, LPREGiMMUNERegistry PartnersRigel PharmaceuticalsSanofiSarah CannonSeagen Inc.Sobi, Inc.Stemcell TechnologiesStemline TechnologiesSTEMSOFTTakeda PharmaceuticalsTalaris Therapeuticsthe National Heart, Lung and Blood InstituteU.S. Public Health ServiceVertex PharmaceuticalsVor Biopharma Inc.Xenikos BV
6 · The paper itselfAbstract
backgroundWhen human leukocyte antigen (HLA)-matched donors are not available for hematopoietic stem cell transplants (HSCT), there are no well-accepted guidelines for ranking 7/8 HLA-matched unrelated donors to achieve optimal transplant outcomes. A novel scoring system for ranking HLA mismatches for these donors was investigated.
methodsHigh-resolution HLA types were used to determine amino acid mismatches located in the HLA antigen-recognition domain. The location and physicochemical properties of mismatched amino acids were used to assign scores for peptide binding, T-cell receptor docking, and HLA structure/function. The scores were tested using a cohort of 2319 patients with leukemia or myelodysplastic syndrome who received their first unrelated donor transplant using conventional graft-versus-host disease (GVHD) prophylaxis between 2000 and 2014. Donors were 7/8 HLA-matched with a single HLA Class I mismatch. Primary outcomes were overall survival and acute GVHD.
resultsThe scores did not significantly (p < 0.01) associate with transplant outcomes, although a Peptide Score = 0 (i.e., no differences in peptide binding; N = 146, 6.3%) appears to have lower transplant-related mortality (TRM) compared to higher scores (p = 0.019). HLA mismatches with Peptide Score = 0 were predominately HLA-C*03:03/03:04 (62%), previously reported to be a permissive mismatch, and a group of 28 other HLA mismatches (38%) that showed similar associations with TRM.
conclusionsThis study suggests that HLA mismatches that do not alter peptide binding or orientation (Peptide Score = 0) could expand the number of permissive HLA mismatches. Further investigation is needed to confirm this observation and to explore alternative scoring systems for ranking HLA mismatched donors.
Indexed as
Graft vs Host DiseaseHematopoietic Stem Cell TransplantationHistocompatibility TestingHLA AntigensMyelodysplastic SyndromesAdolescentAdultAgedChildChild, PreschoolFemaleFollow-Up StudiesHumansLeukemiaMaleMiddle AgedHLA AntigensHLA mismatchHSCTscoring systemunrelated donors
Identifiers
PMID39512128
PMCPMC11840805
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390